Aquinox Pharmaceuticals, a Vancouver, BC-based developer of small molecule drugs for cancer and inflammatory diseases, said today it has secured a $25 million second round of venture financing. The deal was led by Ventures West, and included Pfizer Venture Investments, Johnson & Johnson Development Corporation, Baker Brothers Investments and BC Advantage Funds. The money will be used to help Aquinox advance its lead drug candidate into early and mid stage clinical trials against a target called SHIP1.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
